Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors

US11639355B2 · kind B2 · utility

Assignees

• LUOXIN PHARMACEUTICAL (SHANGHAI) CO., LTD. · CN
• SHANDONG LUOXIN PHARMACEUTICAL GROUP STOCK CO., LTD. · CN
• Medshine Discovery Inc. · CN

Inventors

• Kevin X. Chen · Edison, US
• Xiaobing Yan · Baoding, CN
• Jianglei Huang · Shanghai, CN
• Yuekun Nie · Shanghai, CN
• Guoping HU · Shanghai, CN
• Jian Li · Shanghai, CN
• Shuhui CHEN · Shanghai, CN
• Jiaqiang Dong · 浮桥镇, CN
• Tie-Lin Wang · Shanghai, CN

Key dates

• Filing date: Mar 12, 2019
• Grant date: May 2, 2023
• Expiry date: Jul 25, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed is a novel class of MDM2-p53 inhibitor compounds having an imidaxopyrolone structure, and specifically disclosed are compounds represented by formulas (I-1) and (I-2) and pharmaceutically acceptable salts thereof.